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Abstract 
Background: Due to demographical changes the number of elderly patients depending on oral anticoagulation is 
expected to rise. Prolonged bleeding times in case of traumatic injuries represent the drawback of these medications, 
not only in major trauma, but also in superficial wounds. Therefore, dressings capable of accelerating coagulation 
onset and shortening bleeding times are desirable for these patients.
Methods: The hemostatic potential and physical properties of different types of superficial wound dressings 
(standard wound pad, two alginates, chitosan, collagen (Lyostypt®), oxidized cellulose, and QuikClot®) were assessed 
in vitro. For this purpose the clotting times of blood under the influence of the named hemostatics from healthy 
volunteers were compared with Marcumar® or ASS® treated patients. For that, a newly developed coagulation assay 
based on spectrophotometric extinction measurements of thrombin activity was used.
Results: The fastest coagulation onset was observed for oxidized cellulose (Ø 2.47 min), Lantor alginate‑l (Ø 2.50 min) 
and QuikClot® (Ø 3.01 min). Chitosan (Ø 5.32 min) and the collagen Lyostypt® (Ø 7.59 min) induced clotting com‑
paratively late. Regarding physical parameters, QuikClot® showed the lowest absorption capacity and speed while 
chitosan and both alginates achieved the highest. While oxidized cellulose displayed the best clotting times, unfortu‑
nately it also revealed low absorption capacity.
Conclusions: All tested specimens seem to induce clotting independently from the administered type of oral antico‑
agulant, providing the possibility to neglect the disadvantage in clotting times arising from anticoagulation on a local 
basis. QuikClot®, oxidized cellulose and unexpectedly alginate‑l were superior to chitosan and Lyostypt®. Due to its 
additional well‑known positive effect on wound healing alginate‑l should be considered for further investigations.
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Background
Diseases such as arteriosclerosis, atrial fibrillation (AF), 
arterial hypertension and diabetes mellitus increase the 
risk for cardiac diseases and thromboembolic events. In 
line with an aging population, this is expected to lead to 
an increased number of patients requiring oral antico-
agulants (OACs) or antiplatelet therapies (APT) in the 
future [1]. The prevalence of atrial fibrillation is about 
2 % in the overall population and will prospectively rise 
continuously to about 10  % in people over the age of 
80 years [2, 3]. Already, a large number of humans over 
60 years depend on drugs like acetylsalicylic acid (ASS®), 
P2Y12 antagonists (e.g. clopidogrel, ticagrelor), vitamin 
K antagonists (VKA, e.g. Marcumar®), new oral antico-
agulants (NOACs, e.g. rivaroxaban) or even a combined 
anticoagulation therapy (ACT) to treat and prevent 
thromboembolism, myocardial infarction and strokes [4, 
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for bleeding complications after traumatic injuries or sur-
gical procedures [6, 7].
In the last two decades, regimes regarding the periop-
erative management of ACT were developed [8, 9]. These 
“bridging” regimes exist for each kind of OAC, APT or 
their combinations [10] and are widely established for 
planed interventions and surgery. However, they are 
inapplicable in case of acute trauma with major hemor-
rhage. The iatrogenic coagulopathy can be addressed to 
a certain degree by performing systemic damage control 
resuscitation via transfusion [11] or locally by hemostatic 
dressings combined with local pressure as used in emer-
gency care [12]. Still, surgical procedures and hemor-
rhage control of patients receiving ACT is challenging.
Furthermore, minor bleedings of trivial wounds also 
represent a daily challenge for patients with ACT. A sim-
ple incisional wound under ACT can bleed up to 20 min 
or longer if untreated (personal experience). The deceler-
ated clotting which leads to discomfort and stress to the 
wounded person may not necessarily represent a major 
threat demanding an acute intervention. But as there is 
a rising number of persons concerned, these minor inju-
ries become more troublesome and a reoccurring prob-
lem for the individual. In addition, it has been shown 
that long-term intake of OAC is associated with reduced 
quality of life, including bleeding complications and the 
fear for such [13]. It can be assumed that repeated inju-
ries with prolonged bleeding times, especially in case of 
impaired wound healing resulting from comorbidities 
or reopening, further foster a reduction in quality of life. 
Furthermore, it needs to be considered that coagulation 
represents the first phase of wound healing [14]. There-
fore, a prolonged primary coagulation could impair the 
healing process and increase the risk of wound chronifi-
cation even in small wounds. Hemostatic dressings, like 
QuikClot®, used in emergency care demonstrate a useful 
tool to control bleeding faster [15, 16] and thus, should 
be transferred to daily practice.
In view of the outlined complications and quality of 
life limitations for patients under ACT this study aimed 
to evaluate different new as well as established kinds of 
wound contact material regarding their capability of 
accelerating coagulation times in  vitro. Additionally, 
physical parameters relevant for a wound dressing like 
weight, absorption capacity and speed, tissue adhesion 
as well as pH and temperature influence of all specimens 
were assessed. Based on these results the most suitable 
hemostatic superficial wound dressings were identified 
for future investigations. So far, the established dressings 
are only used in emergency care and warfare medicine 
but may represent a promising option for daily clini-
cal practice and home care to handle excessively bleed-
ing superficial wounds. To determine their potential in 
accelerating blood coagulation a novel in  vitro method 
based on a chromogenic assay was used.
Methods
Specimen and physical properties
Seven different wound pads (Fig. 1; Table 1) were evalu-
ated in respect to their potential to accelerate coagula-
tion. Additionally, physical properties such as weight, 
absorption capacity and time needed to absorb 50  µl 
of whole blood were determined for all pads. For these 
analyses, specimens were cut into pieces of 1  cm2 
(0.5  cm ×  2  cm for spectrophotometric measurements, 
1  cm  ×  1  cm for physical property tests). Only Quik-
clot® was prepared in pieces of 0.5 cm × 4 cm and sub-
sequently laid double due to its thinness resulting in the 
same size (0.5 cm × 2 cm) as all tested pads. In case of 
using QuikClot® as a plaster pad the double layer would 
be its reasonable application.
Dry weight of all specimen (1 cm2 pieces) were deter-
mined by measuring three samples using a fine scale (ALJ 
160-4M; Kern & Sohn GmbH, Balingen-Fromern, Ger-
many) and mean  ±  SD were calculated. Subsequently, 
fresh whole blood from healthy volunteers was stepwise 
administered to the pads until saturation and maximum 
absorption capacity in µl/cm2 was determined.
To determine the absorption speed of the investigated 
dressings (in seconds) 50  µl of fresh whole blood was 
applied to the samples unsing a 100 µl pipette (Eppendorf 
AG, Hamburg, Germany) and time needed to absorb the 
blood was measured by stopwatch. All measurements 
were performed in triplicates.
Tissue adhesion, pH and temperature measurement
A 1.5  cm  ×  3  cm piece of each tested pad was placed 
on fresh porcine skin [22] and exposed to 50 µl of fresh 
whole blood from untreated, healthy volunteers for 24 h. 
Within this period the blood coagulated and agglutinated 
with the pads and thereby attached to the porcine skin. 
The adhesive strength of each pad to the porcine skin 
was determined with a digital force gauge (Sauter, Balin-
gen, Germany) in a peak-tension mode with a speed of 
0.5 mm/s.
The pH and temperature differences between the 
wound pads submerged in human fresh frozen plasma 
(FFP) of untreated, healthy volunteers were determined 
at baseline, after 15, 30, 60 and 90  min. Changes were 
measured by the inoLab® pH 720 (WWT, Weilheim, 
Germany).
Subject groups and sample collection
The study was conducted with 20 untreated volun-
teers (group A), 20 patients treated with the coumarin 
derivative Marcumar® (group B) and 30 patients with 
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daily intake of acetylsalicylic acid (ASS®; group C). For 
untreated volunteers no intake of anticoagulants in the 
last 10 days was mandatory.
In advance, ethical approval was obtained by the eth-
ics committee (Witten/Herdecke University, Germany; 
FN: 16/2014). The inclusion criteria for all groups were 
as followed: Caucasian and age ≥50  years for homoge-
neity of the study group, as well as the signed informed 
consent. In the Marcumar® group an international nor-
malized ratio (INR) of >1.5 and ≤3.5 was defined as 
additional inclusion criteria while in the ASS® group 
the regular daily intake of 100 mg ASS® was a necessary 
requirement. Underlying diseases requiring therapeutic 
or prophylactic anticoagulation were atrial fibrillation 
for all Marcumar® treated patients (n  =  20) and coro-
nary heart disease (CHD; n  =  27) or peripheral arte-
rial disease (PAD; n  =  3) for the ASS® group. General 
exclusion criteria were defined as followed: attendance 
to other clinical trials, hereditary hemorrhagic diathesis, 
hereditary coagulopathy, pregnancy, HIV, hepatitis B or 
C infection, administration of anticoagulants of other 
specification or combined treatments of diverse oral 
anticoagulants, chemotherapy, cortisone administration, 
liver insufficiency, Quick value <15 %, Hb value <10 mg/
dl or missing of informed consent. Age, body height (BH) 
and body weight (BW) were documented to calculate the 
body mass index (BMI) as well as the gender to choose 
matched volunteers. In addition, the blood parameters 
hemoglobin (Hb), platelet count, activated partial throm-
boplastin time (aPTT), INR and C-reactive protein (CRP) 
levels were determined. For analyzing the wound pads 
20 ml whole blood samples were collected from each par-
ticipant in S-Monovette® 10 ml blood collection systems 
(Sarstedt AG & Co., Nümbrecht, Germany) containing 
Fig. 1 Macro‑ and microscopic pictures of the investigated specimens (1 cm2). a standard wound pad; b DRACO alginate (‑d); c lantor alginate (‑l); 
d oxidized cellulose; e chitosan; f QuikClot®; g Lyostypt®. (Magnification: 1:1 & 1:100)
Table 1 Investigated dressings
Data on manufacturer, material and mechanism of action
Manufacturer Material Mechanism of action
Wound pad Dr. Ausbüttel & Co. (DRACO), Witten, 
Germany
Viscose, polypropylene/polyethylene  
nonwoven with microperforated PE film
Control dressing (none expected)
Alginate‑d Dr. Ausbüttel & Co. (DRACO), Witten, 
Germany
Carboxymethyl cellulose containing  
calcium alginate
Release of Ca2 ions induces activation of 
platelets and plasmatic coagulation [17]





Resintex Industriale s.r.l., Pieve Emanuele, 
Italy
Oxidized cellulose Unknown; presumably platelet activation 
[18]
Chitosan Heppe Medical Chitosan GmbH, Halle 
(Saale), Germany
Polysaccharide derived from chitin Unknown; presumably platelet activation 
[19]
QuikClot® Z‑MEDICA, LLC, Wallington, USA Kaolin‑impregnated gauze Unknown; presumably concentration 
of procoagulant factors due to water 
absorption and Ca2+ release [20]
Lyostypt® B. Braun Melsungen AG, Melsungen, 
Germany
Bovine collagen derived fleece Platelet adhesion and activation of coagu‑
lation factor XII [21]
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1 ml citrate solution (0.106 mol/l Trisodium citrate) and 
immediately processed as described below.
Analysis of blood samples and specimen
Samples and specimen were prepared and analyzed 
according to a newly designed method which has been 
established, standardized and validated in terms of accu-
racy, precision, specificity, linearity and reproducibil-
ity using a standardized thrombin reference substance 
(Haemochrom Diagnostica, Essen, Germany), but not 
published by peer review to date. Briefly, the method 
for measuring blood coagulation is based on a chro-
mogenic assay [23], at which the formation of throm-
bin, a key player within the coagulation cascade, causes 
the enzymatic cleavage of the chromogenic substrate 
S-2238 (CHROMOGENIX; Instrumentation Laboratory, 
Bedford, USA). The resulting colorimetric change cor-
responds with the clotting time which is further influ-
enced by the use of different fleece wound pads. For this 
purpose, 20  ml of citrate buffered whole blood samples 
were centrifuged at 170×g for 15 min to obtain platelet-
rich plasma (PRP). Sodium citrate of 2000  µl PRP was 
antagonized with 200  µl calcium chloride (2.27  mmol/l 
CaCl2; Carl Roth GmbH & Co. KG, Karlsruhe, Germany). 
Subsequently, 75 µl of antagonized PRP and 125 µl TRIS 
buffer were added to different specimen within a 48-well 
plate (Sarstedt AG & Co., Nümbrecht, Germany). A vol-
ume of 200 µl S-2238 working solution was added to each 
well and optical density (OD) measurements were com-
menced by spectrophotometry (EON™ Microplate Spec-
trophotometer; BioTek Instruments GmbH, Vermont, 
USA).
Spectrophotometry as part of the coagulation assay 
was performed in three phases: A main kinetics run 
measuring the extinction at 405  nm (reaction kinetics) 
and 750  nm (scattering correction) wavelength, as well 
as a pre- and a post-kinetics absorbance measurement at 
900 nm (path length reference) and 977 nm (path length 
test) wavelength. One complete run covered triplicates 
of one patient. Pre- and post-kinetics measurements 
were conducted for later calculations of path length 
corrections which were necessary due to different fluid 
absorption capacities of the tested specimen, resulting in 
varying layer thickness of the examined blood samples. 
Graphs, test results and data reduction were calculated by 
the program Gen5™ 2.0 Data Analysis Software (BioTek 
Instruments GmbH, Vermont, USA) so that mean values 
and standard deviations (STD) were obtained.
Statistical analysis
The study was initially designed to detect a differ-
ence of 0.9 STD in a two group comparison (α =  0.05, 
Power = 80 %; t test). This would require 20 subjects per 
group. Mean values (MV) and standard deviation (STD) 
for each parameter were calculated. Data were evaluated 
by one-way ANOVA using GraphPad Prism 6 software 
(GraphPad Prism, La Jolla, CA, USA). Multiple paired 
comparisons were corrected using the Tukey–Kramer 
method and differences considered to be statistically sig-
nificant at p < 0.05.
Results
Physical features of the wound pads
The weight of QuikClot® (5.1 ± 0.33 mg/cm2) differed sig-
nificantly from all other wound pads (Fig. 2a). Alginate-l 
showed the highest average weight (16.1 ± 0.73 mg/cm2) 
followed by oxidized cellulose (15.7 ± 0.68 mg/cm2). Alg-
inate-l and oxidized cellulose had a significantly higher 
weight than alginate-d and Lyostypt®. For alginate-d and 
chitosan nearly the same weight was measured.
Regarding absorption capacity, QuikClot® showed the 
lowest value with 55  µl/cm2 and hence differs signifi-
cantly from all other analyzed pads including the stand-
ard wound pad (75  µl/cm2). Alginate-d on the contrary 
showed the highest absorption capacity (Fig. 2b), signifi-
cantly higher than for all other tested dressings.
In terms of absorption speed, the standard wound 
pad showed the by far longest time needed (90 ±  11  s) 
to absorb 50  µl of whole blood. Chitosan and alginate-
l needed 20 ± 3 and 16 ± 10 s respectively, which was 
significantly longer compared to other tested specimen. 
All other dressings were able to absorb 50 µl whole blood 
within 3 s.
Adhesive strength, pH and temperature changes
Significantly less strength was necessary to detach chi-
tosan (126.7 ±  16.1  mN) from porks’ skin compared to 
oxidized cellulose and QuikClot® (660.0  ±  106.1  mN; 
572.5  ±  251.0  mN) after 24  h (Fig.  3). Alginate-
l (318.3  ±  154.9  mN) and the standard wound pad 
(342.5 ±  17.7  mN) also showed comparably little adhe-
sion to the porcine skin. For Lyostypt® and alginate-d a 
force of 371.7 ± 100 and 443.3 ± 154.9 mN was neces-
sary for removal, respectively.
The pH of human FFP was significantly lowered by the 
alginate-d and alginate-l compared to the other pads at 
nearly all time points (Table 2). Within the first 30 min, 
oxidized cellulose induced a significantly higher drop in 
pH-value than QuikClot® and chitosan. Lyostypt® dis-
played an acidifying effect after 30  min (up to 90  min) 
with a significantly lower pH-value than chitosan and 
Quikclot®. The two latter dressings seemed to have no 
acidifying effect; their pH-values were in line with those 
of the control and the standard wound pad.
The temperature did not differ between the tested 
specimens and remained constant at 22.7  ±  0.05  °C 
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in human FFP at all measured time points (data not 
shown). In addition, the pH-value of the untreated 
human FFP rose slightly during the 90  min measure-
ment (7.33 ±  0.03–7.64 ±  0.02) while the temperature 
stayed steady.
Patients and volunteers’ data
For all recruited patients blood test results of Hb, plate-
let count, aPTT, Quick value, INR and CRP were gath-
ered (Table 3). Only the aPTT, INR and CRP values of the 
Marcumar® group differed significantly from those of the 
untreated and ASS® group. Regarding BW, BH and BMI 
no significant differences could be observed whithin the 
groups.
Coagulation assay
The spectrophotometric analysis of all tested wound 
pads showed a remarkable significant reduction in clot-
ting time compared to the untreated positive control as 
well as to a standard wound pad (negative control) for all 
three groups (Fig.  4a–c). QuikClot®, oxidized cellulose 
and alginate-l demonstrated significantly faster clotting 
times than the materials chitosan or collagen (Lyostypt®). 
Of the latter, chitosan had the tendency to induce clot-
ting faster than the established Lyostypt®. The coagu-
lation onset of alginate-l is nearly the same (healthy: 
2.46  ±  0.35  min; Marcumar®: 3.06  ±  0.45  min; ASS®: 
2.40 ±  0.24 min) as that of the well known and already 
established QuikClot® (healthy: 3.13 ± 0.39 min; Marcu-
mar®: 2.51 ± 0.43 min; ASS®: 2.59 ± 0.51 min). In con-
trast, alginate-d manufactured by another company (Dr. 
Ausbüttel & Co., Witten, Germany) could not reach this 
level. However, its clotting induction time was still signif-
icantly shorter than that of the standard wound pad.
Comparison of the three groups revealed no signifi-
cant difference in terms of clotting times of a specimen 
when exposed to Marcumar®, ASS® or untreated blood 
samples. Results for clotting times are very equal for the 
individual pad, regardless of the studied group, while 
the control without specimen application showed a rel-
evant difference (healthy: 30.41 ± 8.27 min; Marcumar®: 
39.44 ± 9.51 min; ASS®: 32.56 ± 11.05 min; Fig. 4d).
Discussion
With regard to demographic changes the percentage of 
patients with cardiovascular diseases such as essential 
hypertension, myocardial infarction, strokes, atrial fibril-
lation and heart valve replacements will rise in west-
ern countries [24]. Relating to this fact the number of 
patients in need of APT and ACT will increase rapidly 
[1]. Both therapies and their combinations reduce the 
likelihood of blood clot formation and thereby reduce 
the overall thromboembolic risk. However, this positive 
effect also faces the difficulty of impaired blood clotting 
which becomes dangerous in case of tissue injuries or 
surgical interventions.
While a decelerated coagulation has a lower impact 
in case of small and superficial wounds, it becomes an 
increasing risk after traumatic injuries. Still, minor inju-
ries and the delayed coagulation is already disturbing 
for the individual, diminishes quality of life and might 
even become a burden. Furthermore, patients with 
cardiovascular diseases often show the same risk fac-
tors as stated for the development of chronic wounds 
like higher age, diabetes mellitus, arterial hypertension, 
obesity and tobacco use [25]. Such parallels might lead 
to the co-occurring of both medical conditions with 
the need for intermittent (surgical) local debridement 
Fig. 2 Dry weight (a; in mg/cm2) and absorption capacity (b; in 
µl/cm2) of the investigated specimens. Values are expressed as 
means ± STD. (#p < 0.05 vs. standard wound pad; °p < 0.05 vs. 
alginate‑l; ●p < 0.05 vs. oxidized cellulose; ϫp < 0.05 vs. Lyostypt®; 
*p < 0.05 vs. QuikClot®; ■p < 0.05 vs. chitosan)
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in an anticoagulated patient. Hence, there is a need for 
wound dressings that promote clotting with all benefi-
cial physical properties of a proper wound dressing and 
counter the ACT locally, without decreasing the overall 
systemic thromboembolic risk prophylaxis. In contrast 
to traumatic major bleedings, where some of the tested 
dressings are commonly used, the physical features of a 
plaster pad play an important role at superficial wounds: 
the pad has to be smooth, light, comfortable to wear, and 
especially non-adhesive. Complications from dressing 
changes such as reopening of the wound should not arise.
In order to compare the hemostatic potential of dif-
ferent specimen in  vitro, a new method to measure 
coagulation induction by solid materials was devel-
oped. Tests such as chromogenic assays or platelet func-
tion (aggregometry) are well known and established to 
determine specific activities within the coagulation cas-
cade [26, 27]. Due to poor standardization and different 
methods applied there is no established standardized 
in  vitro method for measuring the hemostatic effect of 
materials such as fleece dressings or other wound pads. 
All of these procedures focus only on fluids with or 
without corpuscular fraction. The attempt to indirectly 
measure the hemostatic effect via thromboelastography 
(TEG) led to results which did not reflect the clinical 
results in terms of induction of hemostasis and clotting 
[28]. The newly developed coagulation assay applied in 
this study uses spectrophotometric determination of 
thrombin activity enabling a standardized, reproduc-
ible and unsusceptible in  vitro method for the objec-
tive measurement of clotting time in solid materials and 
dressings. This facilitates the thorough in  vitro evalua-
tion of newly developed hemostatics prior to in vivo and 
clinical trials.
Several available topical agents such as fibrin sealants, 
silicates and others improve local hemostasis [29–31]. 
However, study designs were not comparable and most 
focused on major hemorrhage in surgical intervention, 
severe trauma or battlefield injuries. The prolonged 
bleeding of superficial everyday wounds are insufficiently 
analyzed [29, 32].
Fig. 3 Force (in mN) needed to remove agglutinated specimens 
from porcine skin after 24 h. Values are expressed as means ± STD. 
(*p < 0.05 vs. chitosan)
Table 2 pH value of  different wound pads submerged in  human fresh frozen plasma (FFP) of  volunteers at  baseline, 
after 15, 30, 60 and 90 min
Values are expressed as means ± STD
a–h Means differ significantly (p < 0.05, One-way ANOVA) to indicated superscripted dressings. a Wound pad, b alginate-d, c alginate-l, d oxidized cellulose, e chitosan,  
f Quickclot®, g Lyostypt®, h control
Control Wound pad Alginate-d Alginate-l Oxidized Cel-
lulose
Chitosan Quikclot® Lyostypt®
Baseline 7.33 ± 0.03b 7.34 ± 0.03b 7.08 ± 0.04a,c,d,e,f,g,h 7.26 ± 0.08e,f 7.25 ± 0.04e,f 7.43 ± 0.04b,c,d 7.44 ± 0.06b,c,d 7.33 ± 0.05b
30 min 7.48 ± 0.02 7.47 ± 0.02c 7.35 ± 0.04e,f 7.29 ± 0.13e,f,h 7.4 ± 0.07f 7.53 ± 0.02b,c,g 7.57 ± 0.03b,c,d,g 7.36 ± 0.02e,f
60 min 7.57 ± 0.04c 7.56 ± 0.04b,c 7.2 ± 0.01a,c,d,e,f,g,h 7.38 ± 0.11a,b,d,e,f,h 7.53 ± 0.05b,c 7.61 ± 0.02b,c,g 7.65 ± 0.03b,c,g 7.4 ± 0.04b,e,f
90 min 7.64 ± 0.03b,c,g 7.63 ± 0.03b,c,g 7.23 ± 0.04a,c,d,e,f,g,h 7.47 ± 0.08a,b,e,h 7.55 ± 0.05b,f 7.66 ± 0.02b,c,g 7.7 ± 0.01b,c,d,g 7.5 ± 0.02a,b,e,f,h
Table 3 Patients’ data and blood parameters
Values are expressed as means ± STD








258.6 ± 77.87 239.3 ± 87.37 255.5 ± 11.4
INR 0.99 ± 0.15* 2.35 ± 0.67 0.98 ± 0.05*
aPTT (s) 30.14 ± 4.05* 45.9 ± 12.46 30.22 ± 6.24*
Hb (g/dl) 13.94 ± 1.18 12.94 ± 3.44 13.61 ± 1.26
CRP (mg/dl) 8.76 ± 7.52* 38.48 ± 12.87 5.97 ± 6.15*
Age (years) 62.4 ± 7.4 76.2 ± 9.1 68.3 ± 11.4
Body weight (kg) 82.4 ± 10.0 84.2 ± 19.9 86.8 ± 21.2
Body height (cm) 170 ± 1.0 171 ± 8.0 172 ± 9.0
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Wound pads with hemostatic features are well known 
from emergency and combat medicine with Quik-
Clot® Combat Gauze (Z-MEDICA, Wallingford, USA), 
Lyostypt® (B. Braun Melsungen AG, Melsungen, Ger-
many), Celox® (MedTrade Products Ltd, Cheshire, UK), 
WoundStat® (TraumaCure, Bethestta, MD, USA) and a 
dry fibrin sealant dressing (Ethicon®, Johnson and John-
son, Sommervilee, USA) as common representatives. 
According to the FDA classification (Food and Drug 
Administration, Dept. of Health and Human Services, 
USA) all pads, except the fibrin sealant, are class II prod-
ucts and therefore do not contain released substances.
QuikClot® Combat gauze is composed of kaolin-
impregnated rayon and polyester hemostatic dressing 
that advances coagulation by rapidly absorbing fluid. 
This results in an accumulation and concentration of cel-
lular blood components and coagulation factors at the 
wound site. Although QuikClot® demonstrated accel-
erated coagulation induction regardless of the applied 
ACT (Marcumar®, ASS® or untreated), it showed poor 
results in terms of absorption capacities and was not able 
to absorb the necessary blood volume of acute bleeding 
superficial wounds. Due to the fact that QuikClot® 
showed the second highest adhesive strength the risk 
of reopening of the wound upon removal is increased. 
Furthermore, the previously produced QuikClot® based 
on zeolite derived from volcanic rock was replaced by 
the manufacturer in 2010 due to adverse effects, such as 
(micro-)embolism and tissue damage caused by an exo-
thermic reaction [33, 34].
Oxidized cellulose, manufactured from wood pulp, 
consists of a polyanhydroglucuronic acid. Up to 
date, the exact mechanism of its hemostatic action is 
unknown. Presumably, clotting is supported by physi-
cal effects rather than interfering with coagulation cas-
cade components [35]. It is mainly used in the surgical 
setting since it is absorbable and can therefore be left 
in place within body cavities. In this in vitro study oxi-
dized cellulose had comparable hemostatic capabili-
ties to QuikClot® and was superior to Lyostypt®. Blood 
absorption capacity of oxidized cellulose was signifi-
cantly better than for QuikClot® indicating an advan-
tage for the use as a superficial wound dressing. On the 
other hand its feature to dissolve as well as its strong 
Fig. 4 Clotting time (in minutes) induced by the different investigated wound pads and a control without specimen application. Results were 
assessed via spectrophotometric extinction measurement of thrombin activity. a Healthy volunteers, b Marcumar® patients, c ASS® patients, d sum‑
marized graphic depiction of all groups (statistics not reported). Values are expressed as means ± STD. (*p < 0.05 vs. control; #p < 0.05 vs. standard 
wound pad; °p < 0.05 vs. alginate‑d; ●p < 0.05 vs. oxidized cellulose; ϫp < 0.05 vs. Lyostypt®)
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adhesion might be disadvantageous for treating super-
ficial wounds.
The hemostatic effect of chitosan which is a polysac-
charide belonging to the group of biopolymers is not 
exactly known either. It has been discussed to induce 
vasoconstriction leading to a local accumulation of blood 
cells and clotting factors. Additionally, chitosan intensi-
fies thrombocyte adhesion and aggregation at damaged 
tissue [36]. However, the efficacy of inducing and accel-
erating clotting is still being discussed, as several studies 
showed a significant reduction in bleeding and mortal-
ity [37–39] while others deny these effects [40, 41]. In 
terms of physical parameters, chitosan showed good 
results in absorption capacity and dry weight, but com-
paratively slow absorption speed. Regarding adhesion to 
porcine skin it demonstrated the lowest adhesion of all 
tested specimen. The clotting time was six-fold acceler-
ated compared to alginate-d and even predominated 
the established collagen Lyostypt®. Thus, and due to 
good additional haptic abilities, chitosan might be suit-
able as a plaster wound pad, particularly for wounds with 
high exudation rates with the further option to control 
hemostasis.
Derived from bovine corium, microfibrillar collagen, 
such as Lyostypt®, induces hemostasis accompanied by 
low rates of tissue reaction and fast absorption capacities 
[42] and demonstrated hemostatic effects in animal stud-
ies [43, 44]. These effects are based on the promotion of 
platelet aggregation in which thrombocytes adhere to the 
collagen while undergoing a morphological change dur-
ing the process of clotting. This results in an additional 
clot strengthening. Despite the coagulation promoting 
effect of Lyostypt®, nearly all tested specimen of the pre-
sent study induced coagulation faster. Quikclot® and alg-
inate-l showed significantly faster clotting times for both 
groups with ACT. Even though good results of the adhe-
sion and absorption tests indicate no concerns for the 
usage of Lyostypt® as a plaster wound pad, its handling is 
difficult [43] and superior results reported in other stud-
ies [45, 46] could not be confirmed.
Alginate dressings are often used in the management 
of chronic wounds due to their bacteriostatic effect and 
high wound fluid absorption capability [47, 48] which 
is in line with the results of the present study. Due to 
limited information and evidence about the hemo-
static potential of alginates, different kinds were tested 
in this study revealing variations in the range of ±15  % 
(alginate-d vs. alginate-l) in terms of absorption capac-
ity. The known blood absorption capacities of alginates 
resulting in advanced coagulation [49] could be con-
firmed for alginate-l in the in  vitro assay. The clotting 
time was equal to that of Quikclot® or oxidized cellulose. 
Alginate-d however, showed comparatively poor results, 
but still significantly predominated the standard plaster 
wound pad. Furthermore, no disturbance of wound heal-
ing or other adverse effects have been reported for algi-
nates [49]. The combination of all declared features of the 
alginate-l make it the first choice out of the investigated 
superficial wound dressings for the faster induction of 
coagulation combined with its favorable effects on pro-
moting wound healing.
A very interesting result of this in vitro study is the fact 
that all analyzed superficial wound dressings reduced the 
clotting time to the same level regardless of the patients’ 
ACT (ASS® or Marcumar®). In contrast, results from the 
controls of each group without any specimen contact 
showed distinct differences in clotting time indicating 
that the pads are capable of neglecting the anticoagulat-
ing effect of the investigated ACTs in vitro.
In terms of limitations to this study it needs to be 
emphasized, that the presented results represent a first 
in  vitro exploration into the topic of hemostatic dress-
ings for superficial wounds in anticoagulated patients. 
The results serve as a foundation for future in vitro and 
in  vivo investigations to further support the reported 
findings in this study. Another limitation regards the 
tested ACTs in this study. Due to the predominant use 
of Marcumar® and ASS® in clinical practice in Germany 
these were chosen for preliminary examinations. In 
light of the present increase in the use of new oral anti-
coagulants (NOACs) such as direct factor Xa inhibitors 
(rivaroxaban) and P2Y12 antagonists (clopidogrel, tica-
grelor) these medications still need to be evaluated in 
order to reach a more general conclusion on the treat-
ment of superficial wounds of patients receiving ACT 
with hemostatic dressings. Such investigations, as well as 
first in vivo tests are currently in the process of planning. 
Regarding the study population the gender proportion 
in the Marcumar® group was not balanced. Inclusion 
of patients treated solely with Marcumar® proved to be 
difficult, since most patients received a double or triple 
ACT (additional application of antiplatelet drugs) which 
has been defined as an exclusion criterion. Also, analy-
sis of patients blood parameters revealed significantly 
increased levels of aPTT and CRP in the Marcumar® 
group. A possible explanation for elevated CRP levels 
could be preceding interventions, as no relevant underly-
ing disease such as infection and no heparin treatment as 
explanation for elevated aPTT levels were reported in the 
investigated study groups. While aPTT level elevation 
under treatment with vitamin K antagonists have been 
reported previously [50], no causal correlation between 
Marcumar® therapy and CRP elevation is known to date. 
Therefore, an influence of elevated CRP levels on the 
reported results in clotting times are not expected, but 
can not be entirely precluded either. Further research 
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is needed to confirm that hemostatic dressings might 
provide an equal induction of clotting for the individual 
patient in superficial wounds, ruling out the disadvantage 
of different ACTs in local hemostasis.
Conclusions
All analyzed superficial wound dressings reduced the 
clotting time to the same level regardless of the patients’ 
investigated ACT. Therefore, the hemostatic effect is 
based on physical (surface) and/or chemical (pH, tem-
perature) interactions between the tested specimen and 
the patients blood, whereby the underlying mechanism 
of hemodilution (blocking platelet aggregation or inter-
ference with the coagulation cascade) seems secondary. 
With regard to the methods the spectrophotometry has 
the potential to be established as an objective method 
of choice for the investigation of clotting at or in solid 
materials.
In the light of the attained results the summarized 
evaluation of the dressings could be ranked as followed: 
Oxidized cellulose  ≥  alginate-l  >  QuikClot®  >  chi-
tosan  >  Lyostypt®  >  alginate-d  >  standard wound pad. 
Differences in prolonged bleeding times (Marcu-
mar® > ASS® > untreated) could be equalized by apply-
ing a local hemostatic agent and therefore lower the risk 
of exaggerated bleeding in superficial wounds for each 
patient to the same level, as the demonstrated in  vitro 
results suggest. Further in  vivo investigations will be 
necessary to support these results. Alginate-L met the 
requirements of a superficial wound dressing best due to 
its fast coagulation induction combined with favorable 
physical properties, such as high absorption capacity and 
low tissue adhesion. Thus, it should be the first choice in 
the local treatment of “small” hemorrhage like bleeding 
skin wounds, in particular due to its additional positive 
effects in wound healing.
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